The body doesn't distinguish between fat and muscle when it's in a caloric deficit.
As powerful weight-loss medications reshape millions of lives, medicine is confronting an uncomfortable truth: the body does not always shed weight wisely, surrendering muscle alongside fat in ways that undermine the very health gains being sought. A drug called apitegromab, tested alongside the GLP-1 medication tirzepatide in a rigorous phase 2 trial, has shown early promise in persuading the body to hold onto lean tissue even as it releases fat. The finding, published in Nature, suggests that the next frontier in obesity treatment may not be losing more weight, but losing it better.
- GLP-1 drugs like Ozempic and Mounjaro are wildly effective at reducing weight, but they strip away muscle alongside fat — a side effect visible enough to earn its own nickname, 'Ozempic butt.'
- Losing 20 to 30 percent of one's weight loss as lean tissue is not merely cosmetic; it accelerates aging, weakens the body, and quietly undermines the long-term success of the treatment itself.
- Apitegromab targets a specific biological pathway that governs muscle preservation, essentially signaling the body to protect lean tissue even during a steep caloric deficit.
- In a randomized, double-blind, placebo-controlled trial, participants taking apitegromab with tirzepatide retained significantly more muscle than those on tirzepatide alone, while losing comparable amounts of fat.
- The drug is not yet approved and must clear larger trials, but it is already reframing the clinical conversation — from how much weight to lose, to what kind of weight to lose.
The rise of GLP-1 weight-loss medications like Ozempic and Mounjaro has brought an unexpected complication: rapid weight loss that doesn't distinguish between fat and muscle. As the body enters a caloric deficit, it breaks down lean tissue at troubling rates — sometimes 20 to 30 percent of total weight lost. The effect has become visible enough to earn a colloquial name, 'Ozempic butt,' shorthand for the sagging appearance that follows significant weight loss without muscle preservation.
A new drug called apitegromab may offer a way forward. In a phase 2 clinical trial — randomized, double-blind, and placebo-controlled — the medication showed meaningful promise in preventing muscle loss when taken alongside tirzepatide, one of the most widely used GLP-1 drugs. Results were published in Nature, lending the findings considerable scientific weight.
Unlike GLP-1 drugs, which suppress appetite and slow digestion, apitegromab works by blocking biological signals that inhibit muscle development. In doing so, it tells the body to preserve lean tissue even as fat is shed. Trial participants taking both drugs retained significantly more muscle than those on tirzepatide alone, without sacrificing fat loss.
The stakes go beyond appearance. Muscle loss accelerates aging, raises injury risk, and reduces metabolic rate — making long-term weight maintenance harder. For older adults or those with limited mobility, the functional consequences can be especially serious.
Apitegromab is not yet approved; this trial was a proof-of-concept study, and larger trials must follow. But if those succeed, it could become a companion therapy for the millions already using GLP-1 medications. More broadly, the research signals a maturing view of weight loss in medicine — one where the goal is not simply to lose weight, but to lose it in a way that leaves the body stronger.
The popularity of GLP-1 weight-loss medications like Ozempic and Mounjaro has created an unexpected problem: people lose muscle along with fat. As they shed pounds, their bodies break down lean tissue at rates that concern doctors and patients alike. The effect is visible enough that it has earned a colloquial name—'Ozempic butt'—a shorthand for the sagging, deflated appearance that can result when someone loses significant weight without preserving the muscle underneath.
Now a new drug called apitegromab may offer a solution. In a phase 2 clinical trial, the medication showed promise in preventing this muscle loss when taken alongside tirzepatide, one of the most widely prescribed GLP-1 drugs. The trial was randomized, double-blind, and placebo-controlled—the gold standard for testing whether a treatment actually works. Results were published in Nature, signaling that researchers believe the findings are substantial enough to warrant serious attention.
The problem apitegromab addresses is real and consequential. GLP-1 medications work by slowing digestion and suppressing appetite, which leads to rapid weight loss. But the body doesn't distinguish between fat and muscle when it's in a caloric deficit. Without intervention, people can lose 20 to 30 percent of their weight loss as lean tissue rather than fat. For someone dropping 50 pounds, that could mean losing 10 to 15 pounds of muscle—strength, metabolic capacity, and structural support that took years to build.
Apitegromab works differently than the weight-loss drugs themselves. Rather than affecting appetite or metabolism, it targets a specific biological pathway involved in muscle growth and preservation. By blocking certain signals that suppress muscle development, the drug essentially tells the body to hold onto lean tissue even as calories drop. In the trial, participants taking apitegromab alongside tirzepatide retained significantly more muscle mass than those on tirzepatide alone, while still losing comparable amounts of fat.
The implications extend beyond appearance. Muscle loss accelerates aging, increases injury risk, and reduces metabolic rate—making it harder to maintain weight loss long-term. For older adults or people with limited mobility, the loss of strength and function can be particularly damaging. Doctors have long worried that the dramatic weight loss from GLP-1 drugs, while beneficial for metabolic health, might come at a cost to physical capability.
Apitegromab is not yet approved for use. The phase 2 trial was a proof-of-concept study, designed to show that the drug is safe and effective enough to justify larger, more rigorous testing. If those subsequent trials succeed, the medication could eventually be prescribed as a companion therapy to GLP-1 drugs, taken by people who want to maximize fat loss while protecting their muscle. For the millions already using these weight-loss medications—and the millions more expected to use them in coming years—such an option could meaningfully improve outcomes.
The research also reflects a broader shift in how medicine thinks about weight loss. It's no longer enough to simply lose weight; the goal is to lose weight in a way that preserves health and function. Apitegromab represents an attempt to fine-tune that balance, to let people benefit from powerful new medications without accepting every side effect that comes with them.
Citas Notables
For someone dropping 50 pounds, that could mean losing 10 to 15 pounds of muscle—strength, metabolic capacity, and structural support that took years to build.— Clinical observation from trial data
La Conversación del Hearth Otra perspectiva de la historia
So people are losing muscle on these weight-loss drugs. How much are we talking about?
Significant amounts. If someone loses 50 pounds on a GLP-1 medication, roughly 10 to 15 of those pounds might be muscle rather than fat. That's not trivial—it's strength and metabolic capacity your body needs.
And that's why they're calling it 'Ozempic butt'?
That's part of it. The term captures the visible sagging that happens when fat disappears but the muscle underneath doesn't stay intact. But the real concern goes deeper than appearance—it's about function and long-term health.
How does apitegromab actually stop that from happening?
It works on a different system than the weight-loss drugs do. Instead of affecting appetite, it blocks signals that suppress muscle growth. Essentially it tells your body to preserve lean tissue even when calories are low.
And the trial showed it works?
In the phase 2 trial, people taking apitegromab with tirzepatide kept significantly more muscle while losing the same amount of fat as people on tirzepatide alone. That's the proof they needed to move forward.
What happens next?
Larger trials to confirm safety and effectiveness. If those succeed, it could eventually be prescribed alongside GLP-1 drugs for people who want to optimize their weight loss—lose fat, keep muscle.